Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EBITDA (2020 - 2025)

Historic EBITDA for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.5 million.

  • Ovid Therapeutics' EBITDA rose 531.53% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.9 million, marking a year-over-year increase of 4106.82%. This contributed to the annual value of -$61.9 million for FY2024, which is 439.26% down from last year.
  • Latest data reveals that Ovid Therapeutics reported EBITDA of -$12.5 million as of Q3 2025, which was up 531.53% from -$5.1 million recorded in Q2 2025.
  • Ovid Therapeutics' EBITDA's 5-year high stood at $176.6 million during Q1 2021, with a 5-year trough of -$26.4 million in Q4 2021.
  • Its 5-year average for EBITDA is -$4.3 million, with a median of -$13.2 million in 2024.
  • In the last 5 years, Ovid Therapeutics' EBITDA soared by 96998.11% in 2021 and then plummeted by 10921.35% in 2022.
  • Over the past 5 years, Ovid Therapeutics' EBITDA (Quarter) stood at -$26.4 million in 2021, then skyrocketed by 53.81% to -$12.2 million in 2022, then tumbled by 49.41% to -$18.2 million in 2023, then soared by 41.05% to -$10.7 million in 2024, then decreased by 16.8% to -$12.5 million in 2025.
  • Its EBITDA was -$12.5 million in Q3 2025, compared to -$5.1 million in Q2 2025 and -$12.5 million in Q1 2025.